Table 2.
Comparison of baseline and follow-up CMR quantitative markers in COVID-19 vaccine–associated myocarditis
| CMR variable | Baseline | Follow-up | P value |
|---|---|---|---|
| LVEDVi, mL/m2 | 81.7 (73.9-89.6) | 75.8 (71.15-84.9) | 0.015 |
| LVESVi, mL/m2 | 34.9 (31.4-42.0) | 32.6 (29.3-34.8) | 0.006 |
| LVEF, % | 54.7 ± 5.94 | 57.7 ± 3.48 | 0.014 |
| LVMI, g/m2 | 51.1 (45.8-57,4) | 48.4 (43.3-51.7) | 0.002 |
| RVEDVi, mL/m2 | 79.4 (70.0-79.4) | 82.1 (72.9-90.0) | 0.093 |
| RVESVi, mL/m2 | 36.4 (28.6-43.7) | 39 (34.0-42.7) | 0.048 |
| RVEF, % | 53.8 ± 5.91 | 54 ± 4.67 | 0.004 |
| LAVI-biplane, mL/m2 | 31.7 (26.4-37.9) | 31.9 (26.5-34.6) | 0.411 |
| LGE mass, g | 7.4 (3.24-12.1) | 1.7 (0.62-3.16) | < 0.001 |
| Global LGE, % of LV mass ≥ 5 SD | 8.6 ± 5.30 | 2.9 ± 2.01 | < 0.001 |
| Global T2, ms | 39.7 ± 2.39 | 37.6 ± 1.89 | 0.001 |
| Global native T1, ms | 1261.9 ± 45.5 | 1203.9 ± 28.2 | < 0.001 |
| Global ECV, % | 32.9 (30.9-37.0) | 30.0 (28.6-32.0) | 0.001 |
Values are presented as median (IQR) or mean ± SD.
CMR, cardiac magnetic resonance; LAVI, left atrial volume indexed to body surface area. LGE, late gadolinium enhancement; LV, left ventricle; LVEDVi, left ventricular end-diastolic volume indexed to body surface area; LVEF, left ventricular ejection fraction; LVESVi, left ventricular end-systolic volume indexed to body surface area; LVMI, indexed left ventricular mass; RV, right ventricle; RVEDVi, right ventricular end-diastolic volume indexed to body surface area; RVEF, right ventricular ejection fraction; RVESVi, right ventricular end-systolic volume indexed to body surface area.